ArticleJournal for immunotherapy of cancer2022
Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse.
Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Review
- Dynamic estimation of metabolic state during CAR T cell production.Cell reports methods · 2026Article
- A framework integrating multiscale in silico modeling and experimental data predicts CAR-NK cell cytotoxicity across target cell types.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma.Blood cancer discovery · 2026Article
- Data-driven computational modeling of CAR-T cell function.Frontiers in immunology · 2026Article
- Anti-CD19 CAR T-cell therapy for autoimmune diseases: from exploratory clinical trials to quantitative pharmacodynamic modeling development.Frontiers in immunology · 2026Review
- Advancements and expanding applications of CAR-T cell therapy.Frontiers in immunology · 2026Review
- Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia.Nature biomedical engineering · 2025Article
- Human preclinical multiple myeloma in vitro models for disease modeling and therapy screening.Journal of biological engineering · 2025Review
- Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies.NPJ digital medicine · 2025Review
- Cancer-on-a-chip for precision cancer medicine.Lab on a chip · 2025Review
- The Potential Use of Digital Twin Technology for Advancing CAR-T Cell Therapy.Current issues in molecular biology · 2025Review
- Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome.PLoS computational biology · 2025Article
- Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome.PLoS computational biology · 2025Article
- Computational modelling of CAR T-cell therapy: from cellular kinetics to patient-level predictions.EBioMedicine · 2025Review
- Mathematical Model of CAR T-Cell Therapy for a B-Cell Lymphoma Lymph Node.Bulletin of mathematical biology · 2025Article
- Mathematical models and computational approaches in CAR-T therapeutics.Frontiers in immunology · 2025Review
- Bispecific antibody (ABL602 2 + 1) induced bistable acute myeloid leukemia kinetics.Scientific reports · 2024Article
- Mathematical modeling insights into improving CAR T cell therapy for solid tumors with bystander effects.NPJ systems biology and applications · 2024Article
- Advances in manufacturing chimeric antigen receptor immune cell therapies.Seminars in immunopathology · 2024Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAdaptive CD19-targeted chimeric antigen receptor (CAR) T-cell transfer has become a promising treatment for leukemia. Although patient responses vary across different clinical trials, reliable methods to dissect and predict patient responses to novel therapies are currently lacking. Recently, the depiction of patient responses has been achieved using in silico computational models, with prediction application being limited.
methodsWe established a computational model of CAR T-cell therapy to recapitulate key cellular mechanisms and dynamics during treatment with responses of continuous remission (CR), non-response (NR), and CD19-positive (CD19
resultsWe revealed critical determinants related to patient responses at remission, resistance, and relapse. For CR, NR, and CD19
conclusionsOur model dissected the mechanism behind distinct responses of leukemia to CAR T-cell therapy. This patient-based computational immuno-oncology model can predict late responses and may be informative in clinical treatment and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.